Showing 1 - 7 results of 7 for search 'Kami J. Maddocks', query time: 0.03s Refine Results
  1. 1
    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study by Paolo Strati, Sven de Vos, Jia Ruan, Kami J. Maddocks, Christopher R. Flowers, Simon Rule, Priti Patel, Yan Xu, Helen Wei, Melanie M. Frigault, Roser Calvo, Martin J.S. Dyer

    Published 2021-07-01
    Get full text
    Article
  2. 2
    Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia

    Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia by Nyla A. Heerema, Natarajan Muthusamy, Qiuhong Zhao, Amy S. Ruppert, Heather Breidenbach, Leslie A. Andritsos, Michael R. Grever, Kami J. Maddocks, Jennifer Woyach, Farrukh Awan, Meixiao Long, Amber Gordon, Caitlin Coombes, John C. Byrd

    Published 2020-05-01
    Get full text
    Article
  3. 3
    Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

    Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study by Johannes Duell, Pau Abrisqueta, Marc Andre, Gianluca Gaidano, Eva Gonzales-Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Christian Kuffer, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles

    Published 2021-08-01
    Get full text
    Article
  5. 5
    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles

    Published 2021-07-01
    Get full text
    Article
  6. 6
    Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib

    Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib by Cecelia R. Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, Heather Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber L. Gordon, Jeffrey A. Jones, Joseph M. Flynn, Samantha M. Jaglowski, Leslie A. Andritsos, Kristie A. Blum, Farrukh T. Awan, Kerry A. Rogers, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin K. Hertlein, James S. Blachly, Jennifer A. Woyach, John C. Byrd

    Published 2017-08-01
    Get full text
    Article
  7. 7
    Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy

    Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy by Joseph H. Azar, John P. Evans, Madison H. Sikorski, Karthik B. Chakravarthy, Selah McKenney, Ian Carmody, Cong Zeng, Rachael Teodorescu, No-Joon Song, Jamie L. Hamon, Donna Bucci, Maria Velegraki, Chelsea Bolyard, Kevin P. Weller, Sarah A. Reisinger, Seema A. Bhat, Kami J. Maddocks, Nathan Denlinger, Narendranath Epperla, Richard J. Gumina, Anastasia N. Vlasova, Eugene M. Oltz, Linda J. Saif, Dongjun Chung, Jennifer A. Woyach, Peter G. Shields, Shan-Lu Liu, Zihai Li, Mark P. Rubinstein

    Published 2023-03-01
    Get full text
    Article

Search Tools: